GlaxoSmithKline (CAI:BIOC) NonCurrent Deferred Liabilities: E£0 Mil (As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlaxoSmithKline NonCurrent Deferred Liabilities?

GlaxoSmithKline CAI:BIOC +20.00% NonCurrent Deferred Liabilities is E£0 Mil as of Sep. 2016.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

GlaxoSmithKline's non-current deferred liabilities for the quarter that ended in Sep. 2016 was E£0 Mil.

GlaxoSmithKline NonCurrent Deferred Liabilities Related Terms

GlaxoSmithKline NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline NonCurrent Deferred Liabilities Chart

GlaxoSmithKline Annual Data
Trend Dec12 Dec13 Dec14 Dec15
NonCurrent Deferred Liabilities
0.00 0.00 0.00 0.00

GlaxoSmithKline Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
What does a NonCurrent Deferred Liabilities of E£0 Mil mean?
GlaxoSmithKline (CAI:BIOC) has a NonCurrent Deferred Liabilities of E£0 Mil as of Sep. 2016. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's NonCurrent Deferred Liabilities too high?
GlaxoSmithKline's current NonCurrent Deferred Liabilities is E£0 Mil.
How does GlaxoSmithKline's NonCurrent Deferred Liabilities compare to PRPH?
GlaxoSmithKline's NonCurrent Deferred Liabilities of E£0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on GlaxoSmithKline and its competitors. GlaxoSmithKline's current NonCurrent Deferred Liabilities is E£0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current NonCurrent Deferred Liabilities of E£0 Mil. The current NonCurrent Deferred Liabilities is E£0 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current NonCurrent Deferred Liabilities is E£0 Mil as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.